Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

Abstract Purpose Emerging evidence shows that immune checkpoint inhibitors lead to durable responses in a variety of cancers, including nasopharyngeal carcinoma (NPC), however, combination approaches (i.e., stereotactic body radiation therapy, SBRT) are required to extend this benefit beyond a subse...

Full description

Bibliographic Details
Main Authors: Jing Lin, Qiaojuan Guo, Zengqing Guo, Tianzhu Lu, Gang Chen, Shaojun Lin, Mei Chen, Chuanben Chen, Jianping Lu, Jingfeng Zong, Lina Tang, Yu Chen, Jianji Pan
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Radiation Oncology
Subjects:
Stereotactic body radiotherapy
PD-1
Immunotherapy
Nasopharyngeal carcinoma
Online Access:https://doi.org/10.1186/s13014-022-02073-8

Internet

https://doi.org/10.1186/s13014-022-02073-8

Similar Items